1. Market Research
  2. > Biotechnology
  3. > Genomics Market Trends
  4. > Global Metabolomics Market

Global Metabolomics Market

  • November 2014
  • -
  • Global Industry Analysts
  • -
  • 191 pages

This report analyzes the worldwide markets for Metabolomics in US$ Million by the following Product Segments: Bioinformatics Tools in Metabolomic Research, Bioanalytical Instruments and Equipment, and Metabolomics Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 34 companies including many key and niche players such as -

AB SCIEX
Agilent Technologies, Inc.
Biocrates Life Sciences AG
Bio-Rad Laboratories, Inc.
Bruker Corporation

Table Of Contents

Global Metabolomics Market



I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-2
Quantitative Techniques and Analytics I-3
Product Definitions and Scope of Study I-3
Metabolomics I-3


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
Metabolomics - The Current Spotlight of "Omics" Toolbox II-1
Growth Drivers II-3
Market Barriers and Challenges II-3
Metabolomics: A Regional Perspective II-4
US and Europe Spearhead the Global Metabolomics Market II-4
Asia-Pacific: The Fastest Growing Metabolomics Market II-4
Biotechnology and Pharmaceutical Sectors Drive Metabolomics
Research II-4
Demand for Data Analysis Tools and Software on Rise II-5
Bioinformatics-based Metabolomics Applications Poised to Grow II-5
List of Select Metabolomic Analysis Software II-6
Metabolomics Laboratory Management Systems (LIMS): Growing in
Significance II-7
Synopsis of Select Metabolomic Databases II-8
Some Examples of Metabolomics LIMS II-10
Targeted Metabolomics in Newborn Screening: An Area of Success II-10
Lack of Standardization - A Prime Concern II-11
Competitive Scenario II-11

2. AN INSIGHT INTO METABOLOMICS APPLICATIONS II-12
Metabolomics Gain Rapid Foothold in Drug Discovery and
Toxicology Testing II-12
Metabolomic Research - A Prospective Tool to Validate
Potential Targets II-12
Metabolite Profiling for Biomarker Discovery Gaining Prominence II-13
Table 1: Global Biomarkers Market by Discovery Technology
(2013): Percentage Share Breakdown for Bioinformatics,
Imaging Technologies and Omics Technologies (includes
corresponding Graph/Chart) II-14
Oncology - A Key Focus Area for Metabolomics-Based Biomarker
Discovery II-14
Table 2: World Cancer Incidence by Geographic Region and
Gender (2012): Number of New Cancer Cases Reported (in
Thousands) for Asia-Oceania, Europe, North America, Latin
America and the Caribbean, and Africa (includes corresponding
Graph/Chart) II-15

Table 3: New Cancer Cases in the World by Affected Site
(2012) (in Thousands) (includes corresponding Graph/Chart) II-16

Table 4: World Cancer Mortality by Geographic Region and
Gender (2012): Number of Cancer-Related Deaths (in
Thousands) for Asia-Oceania, Europe, North America, Latin
America and the Caribbean, and Africa (includes corresponding
Graph/Chart) II-16
Role of Metabolomics in Personalized Medicine II-17
Table 5: Global Population Statistics for the 65+ Age Group
(2013) (includes corresponding Graph/Chart) II-18

Table 6: %Growth of 65+ Population in North America, Europe,
Asia, and Latin America (includes corresponding Graph/Chart) II-19
Food and Nutrition Looks Up to Metabolomics II-19
Metabolomic Profiling in Food Safety Testing: An Opportunity
to Tap II-20
Global Food Safety Concerns: A Review II-20
Biotechnology and Bioinformatics - The Backbone of New
Testing Technologies II-21
Plants and Agriculture: Metabolomics to Play a Vital Role II-22
Metabolites Present in Select Agricultural Crops II-23
Metabolomics Research on Tomato and Potato Crops II-23
Metabolomics for Environmental Sciences II-23
Nutrigenomics to Benefit from Metabolomics Approach II-24

3. AN INSIGHT INTO SELECT SEPARATION AND DETECTION TECHNOLOGIES II-26
A Primer II-26
Separation and Detection Techniques: A Review II-26
Separation Techniques II-26
Gas chromatography (GC) II-26
Capillary Electrophoresis (CE) II-26
High Performance Liquid Chromatography (HPLC) II-26
Ultra Performance Liquid Chromatography (UPLC) II-26
Detection Techniques II-27
Mass spectrometry (MS) II-27
Nuclear Magnetic Resonance (NMR) Spectroscopy (NMR) II-27
Surface-based Mass Analysis II-27
Common and Prospective Technologies in Metabolite Profiling II-27
Noteworthy Trends II-28
High Performance Liquid Chromatography (HPLC) Dominates the
Market II-28
Major Trends in Gas Chromatography: A Quick Review II-28
Advances in GC Technology II-29
Hyphenated Technologies: Order of the Day II-30
Liquid Chromatography Gains Space in Metabolomics Analysis II-30
MS Systems with UHPLC: A Novel Fusion II-31
HILIC Systems Soaring in Popularity II-31
Capillary Electrophoresis Gains Prominence II-32

4. PRODUCT OVERVIEW II-33
Metabolomics - Introduction II-33
Metabolome II-34
Metabolites II-34
Metabolomics Evolution over the Years II-34
Metabolomics Vs. Metabonomics II-35
Analytical Methods II-35
Key Application Areas II-35
Toxicity Assessment/Toxicology II-35
Functional Genomics II-36
Nutrigenomics II-36
Conceptual Approaches in Metabolomics II-36
Target Analysis II-36
Metabolite Profiling II-36
Metabolomics II-36
Metabolic Fingerprinting II-36
Technological Advancements in Metabolomics II-37
Metabolomics as Systems Biology Tool II-37
Metabolomics: A Link between Genetics and Ecology II-38
Limitations II-38
An Overview of Metabolomics Research II-38
Adoption of Metabolomics Research by Type of Entity II-38
Implementation of Metabolomics Research by Nature of Study II-38
Implementation of Metabolomics Research by Type of Laboratory II-38
Key Issues Associated with Metabolomics Study II-38

5. PRODUCT INTRODUCTIONS/INNOVATIONS II-39
BIOCRATES Life Sciences Introduces Metabolomics-based Bile
Acids Kit II-39
Waters Corporation Releases New Data Analysis Software
Packages for Proteomics and Metabolomics/Lipidomics Analyses II-39
Researchers Demonstrates Biocrates' AbsoluteIDQ p180
Metabolomics Test Kit to Predict Alzheimer's Disease II-39
Metabolon Introduces Quantose IRâ„¢ Prediabetes Test II-39
Metabolon Rolls Out Fourth Generation DiscoveryHD4â„¢
Metabolomics Platform II-39
Bruker Introduces Next-Generation GC-APCI II GC-MS Interface
with Automatic MS Calibration II-40
Bruker Introduces MS-based Solutions and Systems II-40
Metabolon Announces Expansion of Biochemical Profiling
Capabilities II-40
Health Diagnostic Laboratory Introduces Quantoseâ„¢-based New
Diabetes Prevention and Management Panel II-40
Bruker Launches COMPACT LC-QqTOF Mass Spectrometer II-40
BIOCRATES to Introduce Thermo Edition of AbsoluteIDQ® p150 II-40
Shimadzu Introduces GC/MS Metabolite Database Ver. 2 II-41
Shimadzu Releases New LC/MS/MS Method Package for Primary
Metabolites II-41
BIOCRATES Life Sciences to Introduce Waters Xevo® TQ MS
Editions for AbsoluteIDQ® p180 und p150 II-41

6. RECENT INDUSTRY ACTIVITY II-42
Metabolon Collaborates with Metdia Biotech II-42
Metabolon and Baylor College of Medicine Collaborate to Launch
Global MAPS for Inborn Errors of Metabolism II-42
Metabolomic Diagnostic Secures €750,000 Seed Investment II-42
Metabolon Enters into Collaboration with GlaxoSmithKline II-42
Metabolomic Discoveries Enters into Distributorship Agreement
with Filgen II-42
Metabolon Inks Collaboration Agreement with Human Longevity II-42
Metabolon Collaborates with the Carlos Slim Institute, Clinica
Ruiz and Patia II-43
Global Genomics Group to Partner with Metabolon II-43
Human Metabolome Technologies Secures Patent for Method of
Measuring Ethanolamine Phosphate II-43
Metabolon and Bostwick Laboratories Enter into Marketing
Agreement II-43
IMDEA Food Collaborates with Metabolon to Advance Nutrition-
based Personalized Medicine II-43
University of Alberta, BGI Shenzhen and MTI Collaborate to
Commercialize PolypDxâ„¢ Metabolomic-based Diagnostic Test II-43
Agilent Technologies Collaborates with DGIST on
Neurometabolomics Research II-44
DHMRI Enters into Strategic Alliance with Metabolon II-44
AB SCIEX, Genedata, and LECO Enter into Technology Partnership II-44
Matrix-Bio Enters into Metabolomics Biomarker Licensing
Agreement with Quest II-44
Chenomx Collaborates with Spain's Centre for Omic Sciences II-44
Agilent Collaborates with Spain's Centre for Omic Sciences II-44
Metabolon Renews Multi-Year Agreement with Syngenta II-44
Human Metabolome Technologies Inaugurates New Office in the US II-45
LECO Enters into Agreement with DOE's Lawrence Berkeley
National Laboratory II-45
Metabolon Acquires Lipomics Technologies II-45
Takeda and Metabolon Enter into Long-Term Research Alliance II-45
Biocrates Enters into Distribution and Co-Marketing Agreement
with MATERLAB and ONKOGEN Diagnostik II-45
Waters and Nonlinear Dynamics Enter into Agreement to Co-
Develop New Analytical Solution II-45

7. FOCUS ON SELECT PLAYERS II-46
AB SCIEX (US) II-46
Agilent Technologies, Inc. (US) II-46
Biocrates Life Sciences AG (Austria) II-47
Bio-Rad Laboratories, Inc. (US) II-48
Bruker Corporation (US) II-49
Chenomx, Inc. (Canada) II-49
Human Metabolome Technologies, Inc. (Japan) II-50
LECO Corporation (US) II-50
Metabolon, Inc. (US) II-50
Metanomics GmbH (Germany) II-51
Shimadzu Corporation (Japan) II-51
SiDMAP, LLC (US) II-52
Thermo Fisher Scientific, Inc. (US) II-52
Life Technologies Corp. (US) II-53
Waters Corporation (US) II-54

8. GLOBAL MARKET PERSPECTIVE II-55
Table 7: World Recent Past, Current and Future Analysis for
Metabolomics by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (Excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Revenue
Figures in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) II-55

Table 8: World Historic Review for Metabolomics by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (Excluding
Japan), Latin America and Rest of World Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for Years
2008 through 2012 (includes corresponding Graph/Chart) II-56

Table 9: World 13-Year Perspective for Metabolomics by
Geographic Region - Percentage Breakdown of Revenues for US,
Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin
America and Rest of World Markets for Years 2008, 2014 and
2020 (includes corresponding Graph/Chart) II-57

Table 10: World Recent Past, Current and Future Analysis for
Metabolomics by Segment - Bioinformatics Tools in Metabolomic
Research, Bioanalytical Instruments and Equipment, and
Metabolomics Applications Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2013 through
2020 (includes corresponding Graph/Chart) II-58

Table 11: World Historic Review for Metabolomics by Segment -
Bioinformatics Tools in Metabolomic Research, Bioanalytical
Instruments and Equipment, and Metabolomics Applications
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2008 through 2012 (includes
corresponding Graph/Chart) II-59

Table 12: World 13-Year Perspective for Metabolomics by
Segment - Percentage Breakdown of Revenues for Bioinformatics
Tools in Metabolomic Research, Bioanalytical Instruments and
Equipment, and Metabolomics Applications Markets for Years
2008, 2014 and 2020 (includes corresponding Graph/Chart) II-60


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Outlook III-1
Strong Emphasis on Metabolomics Research III-1
Personalized Medicine - An Opportunity for Metabolomics
Technology III-2
Product Introductions/Innovations III-3
Strategic Corporate Developments III-4
Key Players III-7
B.Market Analytics III-13
Table 13: US Recent Past, Current and Future Analysis for
Metabolomics Analyzed with Annual Revenue Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-13

Table 14: US Historic Review for Metabolomics Analyzed with
Annual Revenue Figures in US$ Million for Years 2008 through
2012 (includes corresponding Graph/Chart) III-14

2. CANADA III-15
A.Market Analysis III-15
Outlook III-15
Chenomx, Inc. - A Key Player III-15
B.Market Analytics III-16
Table 15: Canadian Recent Past, Current and Future Analysis
for Metabolomics Analyzed with Annual Revenue Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-16

Table 16: Canadian Historic Review for Metabolomics Analyzed
with Annual Revenue Figures in US$ Million for Years 2008
through 2012 (includes corresponding Graph/Chart) III-17

3. JAPAN III-18
A.Market Analysis III-18
Outlook III-18
Strategic Corporate Developments III-18
Key Players III-19
B.Market Analytics III-20
Table 17: Japanese Recent Past, Current and Future Analysis
for Metabolomics Analyzed with Annual Revenue Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-20

Table 18: Japanese Historic Review for Metabolomics Analyzed
with Annual Revenue Figures in US$ Million for Years 2008
through 2012 (includes corresponding Graph/Chart) III-21

4. EUROPE III-22
A.Market Analysis III-22
Outlook III-22
Personalized Medicine: Opportunities for Growth III-22
Table 19: Population Breakup by Age Group for Select
European Countries: 2012 (As a % of Total Population)
(includes corresponding Graph/Chart) III-23
Strategic Corporate Developments III-24
B.Market Analytics III-25
Table 20: European Recent Past, Current and Future Analysis
for Metabolomics by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets Independently Analyzed
with Annual Revenue Figures in US$ Million for Years 2013
through 2020 (includes corresponding Graph/Chart) III-25

Table 21: European Historic Review for Metabolomics by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets Independently Analyzed with Annual Revenue
Figures in US$ Million for Years 2008 through 2012 (includes
corresponding Graph/Chart) III-26

Table 22: European 13-Year Perspective for Metabolomics by
Geographic Region - Percentage Breakdown of Dollar Revenues
for France, Germany, Italy, UK and Rest of Europe Markets
for Years 2008, 2014 and 2020 (includes corresponding
Graph/Chart) III-27

4a. FRANCE III-28
Market Analysis III-28
Table 23: French Recent Past, Current and Future Analysis for
Metabolomics Analyzed with Annual Revenue Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-28

Table 24: French Historic Review for Metabolomics Analyzed
with Annual Revenue Figures in US$ Million for Years 2008
through 2012 (includes corresponding Graph/Chart) III-29

4b. GERMANY III-30
A.Market Analysis III-30
Outlook III-30
Metanomics GmbH - A Key Player III-30
B.Market Analytics III-31
Table 25: German Recent Past, Current and Future Analysis for
Metabolomics Analyzed with Annual Revenue Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-31

Table 26: German Historic Review for Metabolomics Analyzed
with Annual Revenue Figures in US$ Million for Years 2008
through 2012 (includes corresponding Graph/Chart) III-32

4c. ITALY III-33
Market Analysis III-33
Table 27: Italian Recent Past, Current and Future Analysis for
Metabolomics Analyzed with Annual Revenue Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-33

Table 28: Italian Historic Review for Metabolomics Analyzed
with Annual Revenue Figures in US$ Million for Years 2008
through 2012 (includes corresponding Graph/Chart) III-34

4d. THE UNITED KINGDOM III-35
Market Analysis III-35
Table 29: UK Recent Past, Current and Future Analysis for
Metabolomics Analyzed with Annual Revenue Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-35

Table 30: UK Historic Review for Metabolomics Analyzed with
Annual Revenue Figures in US$ Million for Years 2008 through
2012 (includes corresponding Graph/Chart) III-36

4e. REST OF EUROPE III-37
A.Market Analysis III-37
Outlook III-37
Austria III-37
Finland III-37
Product Introductions/Innovations III-37
Strategic Corporate Developments III-38
Biocrates Life Sciences AG (Austria) - A Major Player III-39
B.Market Analytics III-40
Table 31: Rest of Europe Recent Past, Current and Future
Analysis for Metabolomics Analyzed with Annual Revenue
Figures in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-40

Table 32: Rest of Europe Historic Review for Metabolomics
Analyzed with Annual Revenue Figures in US$ Million for
Years 2008 through 2012 (includes corresponding Graph/Chart) III-41

5. ASIA-PACIFIC III-42
A.Market Analysis III-42
Outlook III-42
Australia III-42
University of Melbourne at the Forefront of Metabolomics
Research III-42
B.Market Analytics III-43
Table 33: Asia-Pacific Recent Past, Current and Future
Analysis for Metabolomics Analyzed with Annual Revenue
Figures in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-43

Table 34: Asia-Pacific Historic Review for Metabolomics
Analyzed with Annual Revenue Figures in US$ Million for
Years 2008 through 2012 (includes corresponding Graph/Chart) III-44

6. LATIN AMERICA III-45
A.Market Analysis III-45
Outlook III-45
Strategic Corporate Developments III-45
B.Market Analytics III-46
Table 35: Latin American Recent Past, Current and Future
Analysis for Metabolomics Analyzed with Annual Revenue
Figures in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-46

Table 36: Latin American Historic Review for Metabolomics
Analyzed with Annual Revenue Figures in US$ Million for
Years 2008 through 2012 (includes corresponding Graph/Chart) III-47

7. REST OF WORLD III-48
Market Analysis III-48
Table 37: Rest of World Recent Past, Current and Future
Analysis for Metabolomics Analyzed with Annual Revenue
Figures in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-48

Table 38: Rest of World Historic Review for Metabolomics
Analyzed with Annual Revenue Figures in US$ Million for
Years 2008 through 2012 (includes corresponding Graph/Chart) III-49


IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 34 (including Divisions/Subsidiaries - 37)

The United States (22)
Canada (2)
Japan (4)
Europe (8)
- Germany (3)
- The United Kingdom (1)
- Spain (1)
- Rest of Europe (3)
Asia-Pacific (Excluding Japan) (1)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
The Chinese Market for DNA Sequencing

The Chinese Market for DNA Sequencing

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Learn about recent advances and trends in the Chinese sequencing industry and market. - Analyze the Chinese sequencing market by workflow, including sample preparation products, ...

Biobanking: Technologies and Global Markets

Biobanking: Technologies and Global Markets

  • $ 6650
  • Industry report
  • November 2016
  • by BCC Research

Use this report to: - Analyze the role biobanks play in the development of new drugs for specific disease treatments. - Learn about the prevailing market size for certain biobank services available ...

Polymerase Chain Reaction (PCR) Technologies and Global Markets

Polymerase Chain Reaction (PCR) Technologies and Global Markets

  • $ 6650
  • Industry report
  • August 2016
  • by BCC Research

This BCC Research report explores the current and future PCR product market, which includes instruments, reagents and consumables, and software and services. It also looks at innovations, market drivers ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.